Cargando…

Interferon (IFN)-λ is a potential mediator in lupus nephritis

OBJECTIVES: Interferon (IFN)-α is thought to be central in the pathogenesis for lupus nephritis (LN) and recent studies also indicate a role for IFNλ. Little is known about these cytokines in the context of treatment response. We studied levels of IFNα and IFNλ in patients with LN in association wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zickert, Agneta, Oke, Vilija, Parodis, Ioannis, Svenungsson, Elisabet, Sundström, Yvonne, Gunnarsson, Iva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Lupus Nephritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133405/ https://www.ncbi.nlm.nih.gov/pubmed/27933198 http://dx.doi.org/10.1136/lupus-2016-000170

Ejemplares similares

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

Value of repeat biopsy in lupus nephritis flares
por: Greloni, G, et al.
Publicado: (2014)

Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis
por: Nawata, Aya, et al.
Publicado: (2023)

Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience
por: Teh, Cheng Lay, et al.
Publicado: (2018)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Immune gene expression and functional networks in distinct lupus nephritis classes
por: Gilmore, Alyssa C, et al.
Publicado: (2022)

Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
por: Malvar, Ana, et al.
Publicado: (2023)

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis
por: Domingues, Vinicius, et al.
Publicado: (2018)

Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity
por: Mao, Zhaomin, et al.
Publicado: (2021)

Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis
por: Moroni, Gabriella, et al.
Publicado: (2022)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus
por: Yates, Drew Joseph, et al.
Publicado: (2020)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis
por: Akhgar, Ahmad, et al.
Publicado: (2023)

Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis
por: Liu, Xiaotian, et al.
Publicado: (2023)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
por: Cooper Blenkinsopp, Selin, et al.
Publicado: (2022)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis
por: Costa-Reis, Patricia, et al.
Publicado: (2022)

Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function
por: Luo, Huiting, et al.
Publicado: (2022)

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders
por: Parikh, Samir V, et al.
Publicado: (2015)

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis
por: Helget, Lindsay N, et al.
Publicado: (2021)

One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria
por: Weeding, Emma, et al.
Publicado: (2022)

Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G(4) deposition: a single-centre retrospective analysis
por: Jiang, Xue, et al.
Publicado: (2022)

A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience
por: Anutrakulchai, Sirirat, et al.
Publicado: (2016)

Molecular signatures of intrarenal complement receptors C3AR1 and C5AR1 correlate with renal outcome in human lupus nephritis
por: Tampe, Désirée, et al.
Publicado: (2022)

Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease
por: Yavuz, Sule, et al.
Publicado: (2022)

Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
por: Gatto, Mariele, et al.
Publicado: (2022)

Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study
por: Anderson, Meghan, et al.
Publicado: (2023)

Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?
por: Ugolini-Lopes, Michelle R, et al.
Publicado: (2017)

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
por: Sada, Kenei, et al.
Publicado: (2022)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
por: Bernatsky, Sasha, et al.
Publicado: (2017)

Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway
por: Chen, Xiao-cui, et al.
Publicado: (2022)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ajcq1cp0kc5opqlsbv2e0jljda